{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T21:52:37Z","timestamp":1781301157033,"version":"3.54.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T00:00:00Z","timestamp":1557878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T00:00:00Z","timestamp":1557878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1038\/s41375-019-0480-2","type":"journal-article","created":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T16:03:58Z","timestamp":1557936238000},"page":"2934-2946","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Convenience, satisfaction, health-related quality of life of once-weekly 70 mg\/m2 vs. twice-weekly 27 mg\/m2 carfilzomib (randomized A.R.R.O.W. study)"],"prefix":"10.1038","volume":"33","author":[{"given":"Philippe","family":"Moreau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Boccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2595-708X","authenticated-orcid":false,"given":"Kim","family":"Cocks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Trigg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Zahlten-Kumeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emre","family":"Yucel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumeet S.","family":"Panjabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,15]]},"reference":[{"key":"480_CR1","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359\u201386.","journal-title":"Int J Cancer"},{"key":"480_CR2","unstructured":"Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M et al. SEER Cancer Statistics Review, 1975-2015, National Cancer Institute. Bethesda, MD, https:\/\/seer.cancer.gov\/csr\/1975_2015\/ based on November 2017 SEER data submission, posted to the SEER web site, April 2018. Accessed 8 June 2018."},{"key":"480_CR3","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1200\/JCO.2016.66.9648","volume":"34","author":"AK Stewart","year":"2016","unstructured":"Stewart AK, Dimopoulos MA, Masszi T, \u0160pi\u010dka I, Oriol A, H\u00e1jek R, et al. Health-related quality of life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma. J Clin Oncol. 2016;34:3921\u201330.","journal-title":"J Clin Oncol"},{"key":"480_CR4","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.20","volume":"7","author":"X Leleu","year":"2017","unstructured":"Leleu X, Kyriakou C, Vande Broek I, Murphy P, Bacon P, Lewis P, et al. Prospective longitudinal study on quality of life in relapsed\/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment. Blood Cancer J. 2017;7:e543.","journal-title":"Blood Cancer J"},{"key":"480_CR5","doi-asserted-by":"crossref","first-page":"289","DOI":"10.4172\/1948-5956.1000430","volume":"8","author":"GL Mortensen","year":"2016","unstructured":"Mortensen GL, Salomo M. Quality of life in patients with multiple myeloma: a qualitative study. J Cancer Sci Ther. 2016;8:289\u201393.","journal-title":"J Cancer Sci Ther"},{"key":"480_CR6","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122\u20138.","journal-title":"Leukemia"},{"issue":"2","key":"480_CR7","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/ejh.13083","volume":"101","author":"Ingemar Turesson","year":"2018","unstructured":"Turesson I, Bjorkholm M, Blimark CH, Kristinsson S, Velez R, Landgren O. Rapidly changing myeloma epidemiology in the general population: increased incidence, older patients, and longer survival. Eur J Haematol. 2018; https:\/\/doi.org\/10.1111\/ejh.13083","journal-title":"European Journal of Haematology"},{"issue":"9","key":"480_CR8","doi-asserted-by":"publisher","first-page":"e412","DOI":"10.3324\/haematol.2017.183475","volume":"103","author":"Sigrun Thorsteinsdottir","year":"2018","unstructured":"Thorsteinsdottir S, Dickman PW, Landgren O, Blimark C, Hultcrantz M, Turesson I et al. Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study. Haematologica 2018; https:\/\/doi.org\/10.3324\/haematol.2017.183475","journal-title":"Haematologica"},{"key":"480_CR9","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1007\/s00520-018-4137-x","volume":"26","author":"F Sparano","year":"2018","unstructured":"Sparano F, Cavo M, Niscola P, Caravita T, Efficace F. Patient-reported outcomes in relapsed\/refractory multiple myeloma: a systematic review. Support Care Cancer. 2018;26:2075\u20132090.","journal-title":"Support Care Cancer"},{"key":"480_CR10","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/leu.2013.185","volume":"27","author":"P Sonneveld","year":"2013","unstructured":"Sonneveld P, Verelst SG, Lewis P, Gray-Schopfer V, Hutchings A, Nixon A, et al. Review of health-related quality of life data in multiple myeloma patients treated with novel agents. Leukemia. 2013;27:1959\u20131969.","journal-title":"Leukemia"},{"key":"480_CR11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ejh.12882","volume":"99","author":"LK Nielsen","year":"2017","unstructured":"Nielsen LK, Jarden M, Andersen CL, Frederiksen H, Abildgaard N. A systematic review of health-related quality of life in longitudinal studies of myeloma patients. Eur J Haematol. 2017;99:3\u201317.","journal-title":"Eur J Haematol"},{"key":"480_CR12","unstructured":"KYPROLIS\u00ae (carfilzomib) [prescribing information]: South San Francisco, CA: Onyx Pharmaceuticals, Inc.; 2018."},{"key":"480_CR13","unstructured":"National Comprehensive Cancer Network (NCCN) 2018 guidelines. http:\/\/www.nccn.org\/ . Accessed October 30, 2018."},{"key":"480_CR14","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1182\/blood-2010-07-294983","volume":"116","author":"S Bringhen","year":"2010","unstructured":"Bringhen S, Larocca A, Rossi D, Cavalli M, Genuardi M, Ria R, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood. 2010;116:4745\u201353.","journal-title":"Blood"},{"key":"480_CR15","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1182\/blood-2010-02-271676","volume":"115","author":"CB Reeder","year":"2010","unstructured":"Reeder CB, Reece DE, Kukreti V, Chen C, Trudel S, Laumann K, et al. Once-versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood. 2010;115:3416\u20137.","journal-title":"Blood"},{"key":"480_CR16","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1185\/030079907X210543","volume":"23","author":"P Barrett-Lee","year":"2007","unstructured":"Barrett-Lee P, Bloomfield D, Dougherty L, Harries M, Laing R, Patel H, et al. An audit to determine the time taken to administer intravenous bisphosphonate infusions in patients diagnosed with metastatic breast cancer to bone in a hospital setting. Curr Med Res Opin. 2007;23:1575\u201382.","journal-title":"Curr Med Res Opin"},{"key":"480_CR17","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1548-5315(11)70357-6","volume":"6","author":"A Oglesby","year":"2009","unstructured":"Oglesby A, Sherif B, Odom D, Leahy M, Qian Y. Time and costs associated with preparing and administering zoledronic acid in patients with breast or prostate cancer and metastatic bone disease. Commun Oncol. 2009;6:494\u2013502.","journal-title":"Commun Oncol"},{"key":"480_CR18","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00520-008-0474-5","volume":"17","author":"LS Schwartzberg","year":"2009","unstructured":"Schwartzberg LS, Stepanski EJ, Walker MS, Mathias S, Houts AC, Fortner BV. Implications of IV monoclonal antibody infusion reaction for the patient, caregiver, and practice: results of a multicenter study. Support Care Cancer. 2009;17:91\u201398.","journal-title":"Support Care Cancer"},{"key":"480_CR19","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3810\/hp.2014.04.1102","volume":"42","author":"F Xie","year":"2014","unstructured":"Xie F, Hophins RB, Burke N, Habib M, Angelis CD, Pasetka M, et al. Time and labor costs associated with administration of intravenous bisphosphonates for breast or prostate cancer patients with metastatic bone disease: a time and motion study. Hosp Pract. 2014;42:38\u201345.","journal-title":"Hosp Pract"},{"key":"480_CR20","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2147\/CMAR.S27693","volume":"4","author":"A Richhariya","year":"2012","unstructured":"Richhariya A, Qian Y, Zhao Y, Chung K. Time associated with intravenous zoledronic acid administration in patients with breast or prostate cancer and bone metastasis. Cancer Manag Res. 2012;4:55\u201360.","journal-title":"Cancer Manag Res"},{"key":"480_CR21","first-page":"31","volume":"23","author":"B Fortner","year":"2009","unstructured":"Fortner B, Viale PH. Health economic analysis of the burden of infusion reactions on patients, caregivers, and provider. Oncology. 2009;23:31\u201336.","journal-title":"Oncology"},{"key":"480_CR22","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/1078155212451197","volume":"19","author":"S Chadda","year":"2013","unstructured":"Chadda S, Larkin M, Jones C, Sykes D, Barber B, Zhao Z, et al. The impact of infusion reactions associated with monoclonal antibodies in metastatic colorectal cancer: a European perspective. J Oncol Pharm Pract. 2013;19:38\u201347.","journal-title":"J Oncol Pharm Pract"},{"key":"480_CR23","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S1470-2045(18)30354-1","volume":"19","author":"P Moreau","year":"2018","unstructured":"Moreau P, Mateos M-V, Berenson JR, Weisel K, Lazzaro A, Song K, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018;19:953\u201364.","journal-title":"Lancet Oncol"},{"key":"480_CR24","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in onocology. J Natl Cancer Inst. 1993;85:365\u201376.","journal-title":"J Natl Cancer Inst"},{"key":"480_CR25","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1046\/j.1365-2141.1999.01206.x","volume":"104","author":"ML Stead","year":"1999","unstructured":"Stead ML, Brown JM, Velikova G, Kaasa S, Wisl\u00f8ff F, Child JA, et al. Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. European Organization for Research and Treatment of Cancer Study Group on Quality of Life. Br J Haematol. 1999;104:605\u201311.","journal-title":"Br J Haematol"},{"key":"480_CR26","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.ejca.2007.04.022","volume":"43","author":"K Cocks","year":"2007","unstructured":"Cocks K, Cohen D, Wisl\u00f8ff F, Sezer O, Lee S, Hippe E, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer. 2007;43:1670\u20138.","journal-title":"Eur J Cancer"},{"key":"480_CR27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/hec.3564","volume":"27","author":"NJ Devlin","year":"2018","unstructured":"Devlin NJ, Shah KK, Feng Y, Mulhern B, Van Hout B. Valuing health-related quality of life: an EQ-5D-5L value set for England. Health Econ. 2018;27:7\u201322.","journal-title":"Health Econ"},{"key":"480_CR28","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1046\/j.1365-2141.1996.352889.x","volume":"92","author":"F Wisl\u00f8ff","year":"1996","unstructured":"Wisl\u00f8ff F, Eika S, Hippe E, Holmberg E, Kaasa S, Palva I, et al. Measurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group. Br J Haematol. 1996;92:604\u201313.","journal-title":"Br J Haematol"},{"issue":"21","key":"480_CR29","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1182\/blood.V122.21.1721.1721","volume":"122","author":"Xavier Leleu","year":"2013","unstructured":"Leleu X, Petrucci MT, Welslau M, Broek IV, Murphy PT, Bottomley A, et al. Psychometric performance of the EORTC Quality-of-life core questionnaire (QLQ-C30) and QLQ-multiple myeloma (QLQ-MY20) in relapsed\/refractory multiple myeloma (RRMM). Blood 2013;122:1721.","journal-title":"Blood"},{"key":"480_CR30","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-14-496","volume":"14","author":"TR Osborne","year":"2014","unstructured":"Osborne TR, Ramsenthaler C, de Wolf-Linder S, Schey SA, Siegert RJ, Edmonds PM, et al. Understanding what matters most to people with multiple myeloma: a qualitative study of views on quality of life. BMC Cancer. 2014;14:496.","journal-title":"BMC Cancer"},{"key":"480_CR31","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1111\/j.1524-4733.2007.00275.x","volume":"10","author":"DL Patrick","year":"2007","unstructured":"Patrick DL, Burke LB, Powers JH, Scott JA, Rock EP, Dawisha S, et al. Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health. 2007;10:S125\u201337.","journal-title":"Value Health"},{"key":"480_CR32","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1200\/JCO.2010.28.0107","volume":"29","author":"K Cocks","year":"2011","unstructured":"Cocks K, King MT, Velikova G, Martyn St-James M, Fayers PM, Brown JM. Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol. 2011;29:89\u201396.","journal-title":"J Clin Oncol"},{"key":"480_CR33","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1600-0609.2012.01788.x","volume":"89","author":"M Delforge","year":"2012","unstructured":"Delforge M, Dhawan R, Robinson D Jr, Meunier J, Regnault A, Esseltine DL, et al. Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial. Eur J Haematol. 2012;89:16\u201327.","journal-title":"Eur J Haematol"},{"key":"480_CR34","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S0895-4356(99)00071-2","volume":"52","author":"KW Wyrwich","year":"1999","unstructured":"Wyrwich KW, Tierney WM, Wolinsky FD. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol. 1999;52:861\u201373.","journal-title":"J Clin Epidemiol"},{"key":"480_CR35","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.jval.2016.11.015","volume":"20","author":"NS McClure","year":"2017","unstructured":"McClure NS, Sayah FA, Xie F, Luo N, Johnson JA. Instrument-defined estimates of the minimally important difference for EQ-5D-5L index scores. Value Health. 2017;20:644\u201350.","journal-title":"Value Health"},{"key":"480_CR36","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1477-7525-5-70","volume":"5","author":"AS Pickard","year":"2007","unstructured":"Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes. 2007;5:70.","journal-title":"Health Qual Life Outcomes"},{"key":"480_CR37","first-page":"163","volume":"11","author":"LD McLeod","year":"2011","unstructured":"McLeod LD, Coon CD, Martin SA, Fehnel SE, Hays RD. Interpreting patient-reported outcome results: US FDA guidance and emerging methods. Expert Rev Pharm Outcomes Res. 2011;11:163\u20139.","journal-title":"Expert Rev Pharm Outcomes Res"},{"key":"480_CR38","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11136-014-0799-0","volume":"24","author":"K Cocks","year":"2015","unstructured":"Cocks K, Buchanan J. Defining responders on the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (30-Item core module) (QLQ-C30) subscales. Qual Life Res. 2015;24:125.","journal-title":"Qual Life Res"},{"key":"480_CR39","first-page":"134","volume":"62","author":"KY Liang","year":"2000","unstructured":"Liang K-Y, Zeger SL. Longitudinal data analysis of continuous and discrete responses for pre-post designs. Sanky\u0101. 2000;62:134\u201348.","journal-title":"Sanky\u0101"},{"key":"480_CR40","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/sim.2249","volume":"25","author":"EF Vonesh","year":"2006","unstructured":"Vonesh EF, Greene T, Schluchter MD. Shared parameter models for the joint analysis of longitudinal data and event times. Stat Med. 2006;25:143\u201363.","journal-title":"Stat Med"},{"key":"480_CR41","doi-asserted-by":"crossref","unstructured":"Fairclough DL. Design and analysis of quality of life studies in clinical trials, 3rd edn. Boca Raton, FL: CRC Press; 2010.","DOI":"10.1201\/9781420061185"},{"key":"480_CR42","unstructured":"Nunnally J, Bernstein I. Psychometric theory. Mcgraw-Hill: New York, NY, 1994."},{"key":"480_CR43","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3324\/haematol.2012.074534","volume":"98","author":"MA Dimopoulos","year":"2013","unstructured":"Dimopoulos MA, Delforge M, H\u00e1jek R, Kropff M, Petrucci MT, Lewis P, et al. Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial. Haematologica. 2013;98:784\u20138.","journal-title":"Haematologica"},{"key":"480_CR44","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jpainsymman.2015.04.016","volume":"50","author":"PJ Atherton","year":"2015","unstructured":"Atherton PJ, Watkins-Bruner DW, Gotay C, Moinpour CM, Satele DV, Winter KA, et al. The complementary nature of patient-reported outcomes (PROs) and adverse event reporting in cooperative group oncology clinical trial: a pooled analysis (NCCTG N0591). J Pain Symptom Manage. 2015;50:470\u20139.","journal-title":"J Pain Symptom Manage"},{"key":"480_CR45","first-page":"119","volume":"5","author":"LT Flores","year":"2012","unstructured":"Flores LT, Bennett AV, Law EB, Hajj C, Griffith MP, Goodman KA. Patient-reported outcomes vs. clinican symptom reporting during chemoradiation for rectal cancer. Gastrointest Cancer Res. 2012;5:119\u201324.","journal-title":"Gastrointest Cancer Res"},{"key":"480_CR46","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1093\/jnci\/djp386","volume":"101","author":"E Basch","year":"2009","unstructured":"Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, et al. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst. 2009;101:1624\u201332.","journal-title":"J Natl Cancer Inst"},{"key":"480_CR47","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374:1621\u201334.","journal-title":"N Engl J Med"},{"key":"480_CR48","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2141.2008.07378.x","volume":"143","author":"SJ Lee","year":"2008","unstructured":"Lee SJ, Richardson PG, Sonneveld P, Schuster MW, Irwin D, San Miguel JF, et al. Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. Br J Haematol. 2008;143:511\u20139.","journal-title":"Br J Haematol"},{"issue":"8","key":"480_CR49","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/ajh.25134","volume":"93","author":"Xavier Leleu","year":"2018","unstructured":"Leleu X, Masszi T, Bahlis NJ, Viterbo L, Baker B, Gimsing P et al. Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed\/refractory multiple myeloma. Am J Hematol. 2018;93:981\u20133.","journal-title":"American Journal of Hematology"},{"key":"480_CR50","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, \u0160pi\u010dka I, Oriol A, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372:142\u201352.","journal-title":"N Engl J Med"},{"key":"480_CR51","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1200\/JCO.2017.76.5032","volume":"36","author":"DS Siegel","year":"2018","unstructured":"Siegel DS, Dimopoulos MA, Ludwig H, Facon T, Goldschmidt H, Jakubowiak A, et al. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2018;36:728\u201334.","journal-title":"J Clin Oncol"},{"key":"480_CR52","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, H\u00e1jek R, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17:27\u201338.","journal-title":"Lancet Oncol"},{"key":"480_CR53","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","volume":"18","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18:1327\u201337.","journal-title":"Lancet Oncol"},{"key":"480_CR54","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-019-0181-0","volume":"9","author":"H Ludwig","year":"2019","unstructured":"Ludwig H, Moreau P, Dimopoulos MA, Mateos M-V, Kaiser MF, Hajek R, et al. Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed\/refractory multiple myeloma. Blood Cancer J. 2019;9:23.","journal-title":"Blood Cancer J"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0480-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0480-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-019-0480-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T02:20:29Z","timestamp":1721269229000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-019-0480-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,15]]},"references-count":54,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["480"],"URL":"https:\/\/doi.org\/10.1038\/s41375-019-0480-2","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,15]]},"assertion":[{"value":"30 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"PM reports honoraria from, and consulting or advisory roles for, Amgen, Celgene, Takeda, Janssen, BMS, Novartis, Millennium, and Onyx Pharmaceuticals. SK reports non-paid consulting and advisory board roles for AbbVie, Celgene, Janssen, Kite Pharma, Merck, and Takeda. RB reports researching funding from Amgen, Genentech, BMS, and AZ; speakers bureau roles for Amgen, Celgene, AZ, Genentech, and AbbVie; and consultancy roles for Pfizer and Sandoz. SI reports research funding from Ono, Takeda, Celgene, Janssen, Novartis, Chugai, Kyowa-Hakko Kirin, Bristol-Myers Squibb, MSD, Gilead, Daiiti Sankyo, Astellas, Toyama Chemical, Teijin Pharma, Abbie and Sanofi; and honoraria from Ono, Takeda, Celgene, Janssen, Bristol-Myers Squibb and Novartis. HG reports research support from Amgen, BMS, Celgene, Chugai, Janssen, Sanofi, Mundipharma, Takeda, and Novartis; advisory board roles for Adaptive Biotechnology, Amgen, BMS, Celgene, Janssen, Sanofi, and Takeda; and speakers bureau honoraria from ArtTempi, BMS, Celgene, Chugai, Janssen, and Novartis. KC reports employment with Adelphi Values; Consulting or advisory role fees from Orthox, Cardioprecision, Amgen, BMS, Endomag, BOC, Cognetivity, and Celgene; and travel and accommodations fees from BMS and Amgen. Andrew Trigg reports employment with Adelphi Values. AZ-K, EY, and SSP report employment with and stock holdings from Amgen. MD reports honoraria from, and advisory board roles for, Takeda, Celgene, Amgen, Janssen, and BMS.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}